Wednesday, July 8, 2026

Patent intelligence · US

US 8871810

Treating critically ill patients with intravenous ibuprofen

granted A61KA61K31/192A61K31/197A61K45/06
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 8
Applicant portfolio 34
Patent details — US 8871810
Jurisdiction
US
Status
granted
Grant date
Oct 28, 2014
Expiration
Oct 23, 2034
Claims
13
CPC classes
A61K, A61K31/192, A61K31/197, A61K45/06
View on Google Patents ↗

Quick answer

US 8871810 (Treating critically ill patients with intravenous ibuprofen) is held by Cumberland Pharmaceuticals Inc.. Status: granted. Granted Oct 28, 2014. Expires Oct 23, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
13
CPC classes
A61K, A61K31/192, A61K31/197, A61K45/06, A61K9/0019, A61K9/08

More from Cumberland Pharmaceuticals Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12161632

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Cumberland Pharmaceuticals Inc. · Expires Dec 5, 2044

    granted
  2. US 11806400

    Injectable ibuprofen formulation

    Cumberland Pharmaceuticals Inc. · Expires Nov 2, 2043

    granted
  3. US 11571412

    Thromboxane receptor antagonists in AERD/asthma

    Cumberland Pharmaceuticals Inc. · Expires Feb 2, 2043

    granted
  4. US 10925860

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Cumberland Pharmaceuticals Inc. · Expires Feb 18, 2041

    granted
  5. US 10751383

    Doses and methods for administering telavancin

    Cumberland Pharmaceuticals Inc. · Expires Aug 20, 2040

    granted
  6. US 10583126

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Cumberland Pharmaceuticals Inc. · Expires Mar 5, 2040

    granted
  7. US 10456380

    Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists

    Cumberland Pharmaceuticals Inc. · Expires Oct 24, 2039

    granted
  8. US 10314824

    Compositions and methods of treating cardiac fibrosis with ifetroban

    Cumberland Pharmaceuticals Inc. · Expires Jun 6, 2039

    granted

Frequently asked questions

What is US patent 8871810?

US 8871810 (Treating critically ill patients with intravenous ibuprofen) is held by Cumberland Pharmaceuticals Inc.. Status: granted. Granted Oct 28, 2014. Expires Oct 23, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8871810?

Cumberland Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.

When does US 8871810 expire?

Our index shows an expiration date of Oct 23, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.